↓ Skip to main content

Cholinesterase inhibitors for Alzheimer's disease

Overview of attention for article published in this source, January 2006
Altmetric Badge

Mentioned by

2 news outlets
5 blogs
41 tweeters
3 patents
1 peer review site
7 Wikipedia pages


1238 Dimensions

Readers on

803 Mendeley
1 CiteULike
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Cholinesterase inhibitors for Alzheimer's disease
Published by
John Wiley & Sons, Ltd, January 2006
DOI 10.1002/14651858.cd005593
Pubmed ID

Birks, Jacqueline S


Since the introduction of the first cholinesterase inhibitor (ChEI) in 1997, most clinicians and probably most patients would consider the cholinergic drugs, donepezil, galantamine and rivastigmine, to be the first line pharmacotherapy for mild to moderate Alzheimer's disease.The drugs have slightly different pharmacological properties, but they all work by inhibiting the breakdown of acetylcholine, an important neurotransmitter associated with memory, by blocking the enzyme acetylcholinesterase. The most that these drugs could achieve is to modify the manifestations of Alzheimer's disease. Cochrane reviews of each ChEI for Alzheimer's disease have been completed (Birks 2005, Birks 2005b and Loy 2005). Despite the evidence from the clinical studies and the intervening clinical experience the debate on whether ChEIs are effective continues.

Twitter Demographics

The data shown below were collected from the profiles of 41 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 803 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United Kingdom 9 1%
United States 6 <1%
Netherlands 2 <1%
Italy 2 <1%
Ireland 2 <1%
Brazil 1 <1%
Pakistan 1 <1%
Sweden 1 <1%
Switzerland 1 <1%
Other 5 <1%
Unknown 773 96%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 152 19%
Student > Ph. D. Student 126 16%
Student > Master 114 14%
Researcher 104 13%
Student > Doctoral Student 46 6%
Other 149 19%
Unknown 112 14%
Readers by discipline Count As %
Medicine and Dentistry 215 27%
Agricultural and Biological Sciences 94 12%
Neuroscience 67 8%
Psychology 52 6%
Pharmacology, Toxicology and Pharmaceutical Science 50 6%
Other 178 22%
Unknown 147 18%